Multiple Myeloma

A collection of features and news articles published in ASH Clinical News related to multiple myeloma.

On location

Deep and Durable Responses Seen With CAR T-Cell Therapy for Pretreated Myeloma

In preliminary efficacy results, treatment with a single low-dose infusion of ciltacabtagene autoleucel (cilta-cel) led to early, deep, and durable responses in patients with...

Does Rheumatic Disease Increase Risk of MGUS Progression to Hematologic Malignancies?

Patients with monoclonal gammopathy of undetermined significance (MGUS) and concomitant non-antibody (Ab)–mediated inflammatory rheumatic diseases are at increased risk of progression to overt multiple...
WIB_icon

Older Patients With Myeloma May Have Suboptimal Response to COVID-19 Vaccination

According to a study published in Blood, older patients with multiple myeloma (MM) experienced reduced efficacy with BNT162b2, Pfizer/BioNTech’s COVID-19 vaccine. However, certain factors...

Tandem High-Dose Influenza Vaccine Offers Durable Seroprotection for Patients With Plasma Cell Dyscrasias

Tandem high-dose influenza vaccination may result in more durable serologic immunity in patients with plasma cell dyscrasias (PCDs), compared with standard vaccination, according to...

Idecabtagene Ciloleucel Induces Deep Responses in Relapsed/Refractory Multiple Myeloma

Treatment with the B-cell maturation antigen−targeted chimeric antigen receptor (CAR) T-cell therapy idecabtagene ciloleucel (ide-cel) showed encouraging efficacy in patients with heavily pretreated relapsed...
WIB_icon

Lenalidomide and Dexamethasone for Older Patients With Multiple Myeloma: Less Is More

According to a study published in Blood, older patients with multiple myeloma (MM) who are taking continuous lenalidomide-dexamethasone (Rd) may be able to switch...

How Can the Myeloma Community Reduce Disparities in Care?

In our March 2021 issue, we reported on findings from a review article examining disparities in outcomes among patients with multiple myeloma (MM), in...

Idecabtagene Vicleucel Approved for Relapsed or Refractory Multiple Myeloma

The FDA has approved idecabtagene vicleucel (ide-cel) as the first B-cell maturation antigen (BCMA)-directed chimeric antigen receptor (CAR) T-cell therapy for the treatment of...

European Commission Approves Selinexor Plus Dexamethasone for Relapsed/Refractory Myeloma

Selinexor, in combination with dexamethasone, has been granted conditional marketing authorization by the European Commission (EC) for the treatment of adult patients with multiple...

FDA Approves Isatuximab-irfc Combination for Relapsed/Refractory Myeloma

Isatuximab-irfc, in combination with carfilzomib and dexamethasone (Isa-Kd), was approved by the U.S. Food and Drug Administration (FDA) on March 31, 2021 for the...